Skip to main content

1 Result(s)

within Maroun Jean Remove this filter

and

  1. No Access

    Article

    A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

    Purpose: The epidermal growth factor receptor (EGFR) appears relevant in the pathogenesis and progression of colorectal cancer. After completing a phase I pharmacodynamic trial of ZD1839, we undertook a dose expa...

    Mary J. MacKenzie, Holger W. Hirte, Goss Glenwood, Maroun Jean… in Investigational New Drugs (2005)